参芪地黄汤加减辅治紫癜性肾炎临床观察  

作　　者：李丹 

机构地区：[1]河南省南阳市第一人民医院儿三科,河南南阳473000

出　　处：《实用中医药杂志》2023年第4期677-680,共4页Journal of Practical Traditional Chinese Medicine

摘　　要：目的:观察参芪地黄汤加减辅治紫癜性肾炎的临床疗效。方法:84例随机分为对照组和治疗组各42例,两组均口服卡托普利、泼尼松,治疗组加用参芪地黄汤加减,疗程4周。结果:治疗组总有效率高于对照组(P<0.05)。治疗后治疗组中医证候积分、尿红细胞数、尿蛋白水平、IgA、IgG、IgM及补体C3、C4均低于对照组(P<0.05)。治疗组CD4+、CD4+/CD8+水平明显高于对照组(P<0.05),CD8+水平低于对照组(P<0.05)。治疗组血清IL-4、IL-21、TGF-β水平低于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:参芪地黄汤加减辅治紫癜性肾炎能提高临床疗效,安全性良好。Objective:To observe the clinical effect of modified Shenqi Dihuang Decoction in the treatment of purpura nephritis.Methods:Eighty-four cases were randomly divided into the control group and the treatment group,42 cases in each group.Both groups were treated with captopril and prednisone,and the treatment group were treated with modified Shenqi Dihuang Decoction in addition.The treatment course was 4 weeks.Results:The total effective rate of the treatment group was higher than that of the control group(P<0.05).After treatment,the scores of TCM syndromes,urine red blood cell count,urine protein level,IgA,IgG,IgM and complement C3 and C4 in the treatment group were lower than those in the control group(P<0.05).The levels of CD4+and CD4+/CD8+in the treatment group were significantly higher than those in the control group(P<0.05),and the level of CD8+was lower than that in the control group(P<0.05).The levels of serum IL-4,IL-21 and TGF-βin the treatment group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Shenqi Dihuang Decoction could improve the clinical efficacy and safety in the treatment of purpura nephritis.

关 键 词：紫癜性肾炎 参芪地黄汤 对照治疗观察 

分 类 号：R692.34[医药卫生—泌尿科学]